Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Background and aims: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate the association between them, and the potential clinical implicatio...

Full description

Bibliographic Details
Main Authors: Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Atherosclerosis Plus
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667089523000378